Loading...
NPI 1295937183 · Biloxi, MS · Retina Specialist (Ophthalmology) Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Anne Baranano is a retina specialist (ophthalmology) physician provider located in Biloxi, Mississippi. This profile covers 14 Medicare and 3 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Anne Baranano |
| Address | 2781 C T Switzer Sr Dr Ste 100 |
| City | Biloxi |
| State | MS |
| ZIP | 39531 |
| Taxonomy | Retina Specialist (Ophthalmology) Physician |
| NPI Enumerated | June 3, 2007 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.7M |
| Medicaid | $530 |
This provider is functionally a retina-focused procedural practice: Medicare billing is dominated by intravitreal anti-VEGF agents and related vitreous procedures, led by J0178 (1.1K claims, $684 avg paid/claim, $777K revenue) and J2778 (2.5K claims, $180 avg paid/claim, $446.4K revenue), with 67028 (1.3K claims, $80 avg paid/claim, $106.6K revenue) also prominent. The top three Medicare codes alone account for 80.0% of this provider's total Medicare revenue, signaling a service-line concentrated on pharmacologic intravitreal therapy and the procedures that accompany it.
Revenue is heavily weighted to Medicare overall: lifetime Medicare revenue is $1.7M versus Medicaid at $530, so the provider is effectively a Medicare-driven practice with negligible Medicaid scale. Medicaid billing is minimal in absolute terms and does not materially contribute to the provider’s revenue base given the $530 lifetime Medicaid figure reported.
Within Medicare, there is a pronounced concentration in a small set of high-revenue codes: J0178 accounts for 46.8% and J2778 accounts for 26.9% of the provider’s Medicare revenue, together representing the majority of the $1.7M stream. This concentration suggests business risk and operational focus tied to the economics and utilization of a few specialty injectable agents.
Though injections dominate revenue, the provider also posts above-peer volumes for diagnostic and evaluation services: 92014 (1.2K claims, $80 avg paid/claim, $96.5K revenue) ranks in the 97th percentile and is described as "notably above typical national volume," and 92134 (2K claims, $27 avg paid/claim, $53.2K revenue) ranks in the 96th percentile and is also "notably above typical national volume." These high-percentile rankings for exam and imaging codes indicate a robust diagnostic throughput that complements the injection-driven procedure mix.
Competitive standing is mixed across codes: for high-revenue injectables the provider is a typical-volume participant nationally—J0178 ranks in the 64th percentile and is labeled "typical, unremarkable volume," while J2778 ranks at the 87th percentile (also "typical, unremarkable volume"). By contrast, J2777 (3.4K claims, $29 avg paid/claim, $99.2K revenue) has a low national revenue rank (13th percentile) despite a large claim count, indicating lower average reimbursement per claim relative to other injectables and a modest national revenue position for that specific drug.
Medicaid activity is narrowly concentrated and entirely captured by three codes: the top three Medicaid codes account for 100.0% of the provider’s Medicaid revenue, with 67028 representing 62.9% ($320), 92014 representing 20.6% ($105), and 92134 representing 16.5% ($84). In-state ranking on Medicaid is weak overall—67028 ranks 14 of 15 providers (7th percentile) and 92014 ranks 398 of 420 (3rd percentile)—underscoring a limited Medicaid footprint compared with peers.
The practice shows a durable tenure in the market: the NPI was enumerated on 2007-06-03 (~19 years ago), indicating long-standing licensure and potential continuity of referral relationships and patient panels in the Biloxi, MS market. That tenure combined with high Medicare volumes for both procedures and diagnostic imaging supports a mature, established retina specialty operation.
Operationally, the code mix—high shares of high-cost biologic injections (J0178, J2778), strong volumes of comprehensive established visits (92014) and OCT imaging (92134)—is consistent with a clinic workflow centered on frequent follow-up visits, imaging-driven monitoring, and recurring intravitreal therapy. Given the Medicare predominance ($1.7M vs $530 Medicaid) and the 80.0% revenue concentration in the top three Medicare codes, payer negotiations, drug sourcing, and injectables utilization strategy are likely primary drivers of this provider’s revenue performance.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
14 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 1,140 | $680 | $777K |
| J2778 | Injection, ranibizumab, 0.1 mg | 2,480 | $180 | $446.4K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 1,330 | $80 | $106.6K |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 3,420 | $30 | $99.2K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 1,210 | $80 | $96.5K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 1,970 | $30 | $53.2K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 730 | $50 | $38.4K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 140 | $110 | $15.4K |
| J9035 | Injection, bevacizumab, 10 mg | 230 | $60 | $13.2K |
| J7999 | Compounded drug, not otherwise classified | 120 | $70 | $8K |
Showing 1–10 of 14
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 14 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
14 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J2778 | 4 | 10 | 1,300 | $180 | $1.3M |
| J0178 | 7 | 20 | 670 | $680 | $990.1K |
| J2777 | 11 | 10 | 8,460 | $30 | $325.2K |
| 67028 | 10 | 30 | 600 | $80 | $107K |
| J7999 | 9 | 10 | 150 | $150 | $64.6K |
| 92014 | 14 | 350 | 170 | $70 | $23K |
| J9035 | 6 | 10 | 210 | $50 | $18.1K |
| 92235 | 12 | 20 | 70 | $90 | $12.1K |
| 92012 | 13 | 220 | 90 | $50 | $9.9K |
| 92134 | 10 | 280 | 80 | $30 | $7.3K |
Showing 1–10 of 14
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
3 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 20 | $20 | $320 |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 20 | $10 | $110 |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 40 | $1 | $80 |
How this provider's Medicaid billing volume and revenue compare to other Mississippi providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Mississippi median
3 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 398 | 420 | 510 | $70 | $92.2K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 14 | 20 | 300 | $30 | $88.7K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 28 | 40 | 70 | $10 | $19.3K |
Other providers in the same ZIP code as Anne Baranano, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.